MarketCap
Facebook
X
Telegram
Akebia Therapeutics Total Assets | AKBA
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Akebia Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 377 M | 221 M | 242 M | 356 M | 529 M | 644 M | 771 M | 997 M | 364 M | 300 M | 143 M | 111 M | 34.7 M | 2.24 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 997 M | 2.24 M | 364 M |
Quarterly Total Assets Akebia Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 350 M | 363 M | 364 M | 346 M | 310 M | 221 M | 207 M | 220 M | - | 242 M | 235 M | 254 M | 277 M | 356 M | 436 M | 530 M | 535 M | 526 M | 602 M | 612 M | 629 M | 644 M | 644 M | 644 M | 644 M | 771 M | 771 M | 771 M | 771 M | 997 M | 997 M | 997 M | 997 M | 364 M | 364 M | 364 M | 364 M | 300 M | 300 M | 300 M | 300 M | 143 M | 143 M | 143 M | 143 M | 111 M | 111 M | 111 M | 111 M | 34.7 M | 34.7 M | 34.7 M | 34.7 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 997 M | 34.7 M | 405 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Ionis Pharmaceuticals
IONS
|
3.52 B | $ 43.5 | 0.62 % | $ 6.96 B |  USA |
 |
Agios Pharmaceuticals
AGIO
|
1.3 B | $ 31.25 | 0.88 % | $ 1.81 B | USA |
 |
Foghorn Therapeutics
FHTX
|
198 M | $ 2.0 | 0.74 % | $ 126 M | USA |
 |
Inhibikase Therapeutics
IKT
|
181 M | $ 2.0 | 0.5 % | $ 197 M | USA |
 |
Kamada Ltd.
KMDA
|
379 M | $ 8.0 | 1.34 % | $ 461 M |  Israel |
 |
Intellia Therapeutics
NTLA
|
842 M | $ 12.75 | 4.0 % | $ 1.38 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
1.53 B | $ 14.5 | 3.19 % | $ 1.43 B | USA |
 |
Viridian Therapeutics
VRDN
|
899 M | $ 19.0 | 2.16 % | $ 1.93 B | USA |
 |
AbbVie
ABBV
|
134 B | $ 265.76 | 1.12 % | $ 470 B | USA |
 |
AbCellera Biologics
ABCL
|
1.36 B | $ 13.78 | 0.29 % | $ 4.12 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
220 M | $ 5.11 | 1.59 % | $ 271 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
94.6 M | $ 4.67 | 4.94 % | $ 895 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
1.56 B | $ 20.11 | 0.8 % | $ 3.39 B | USA |
 |
Achieve Life Sciences
ACHV
|
41.8 M | $ 7.01 | 0.13 % | $ 306 M | USA |
 |
AC Immune SA
ACIU
|
154 M | $ 2.71 | 0.55 % | $ 273 M |  Schweiz |
 |
Aclaris Therapeutics
ACRS
|
160 M | $ 4.27 | 0.79 % | $ 523 M | USA |
 |
Adagene
ADAG
|
78.3 M | $ 2.8 | 0.28 % | $ 165 M |  China |
 |
ADC Therapeutics SA
ADCT
|
323 M | $ 1.23 | 8.85 % | $ 156 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
6.67 M | $ 4.35 | 5.58 % | $ 2.91 M | USA |
 |
ADMA Biologics
ADMA
|
624 M | $ 10.11 | 4.01 % | $ 2.41 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
513 M | $ 29.84 | 5.26 % | $ 4.53 B | USA |
 |
Agenus
AGEN
|
227 M | $ 8.73 | 4.43 % | $ 260 M | USA |
 |
AIM ImmunoTech
AIM
|
5.78 M | $ 0.19 | 5.56 % | $ 308 K | USA |
 |
Akari Therapeutics, Plc
AKTX
|
47.9 M | $ 8.76 | 0.46 % | $ 590 B |  Britain |
 |
Aldeyra Therapeutics
ALDX
|
72.1 M | $ 0.92 | 4.88 % | $ 55.3 M | USA |
 |
Alector
ALEC
|
293 M | $ 1.99 | 9.94 % | $ 205 M | USA |
 |
Aligos Therapeutics
ALGS
|
88.5 M | $ 5.4 | 0.36 % | $ 53.4 M | USA |
 |
Alkermes plc
ALKS
|
2.49 B | $ 42.76 | 2.42 % | $ 7.04 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
416 M | $ 1.5 | 0.33 % | $ 331 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.97 B | $ 219.89 | 0.08 % | $ 28.8 B | USA |
 |
Altimmune
ALT
|
280 M | $ 2.67 | 0.36 % | $ 235 M | USA |
 |
ALX Oncology Holdings
ALXO
|
59 M | $ 1.21 | 1.23 % | $ 64.9 M | USA |
 |
Amgen
AMGN
|
90.6 B | $ 402.98 | 0.08 % | $ 217 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.63 B | $ 25.37 | 0.39 % | $ 1.19 B | USA |
 |
Amarin Corporation plc
AMRN
|
671 M | $ 12.09 | 0.31 % | $ 5.02 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
3.68 B | $ 20.35 | 0.25 % | $ 6.38 B | USA |
 |
AnaptysBio
ANAB
|
317 M | $ 49.2 | 1.38 % | $ 1.43 B | USA |
 |
Anika Therapeutics
ANIK
|
190 M | $ 19.73 | 3.3 % | $ 283 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
1.44 B | $ 72.58 | 0.55 % | $ 1.46 B | USA |
 |
Annexon
ANNX
|
278 M | $ 4.2 | 0.24 % | $ 651 M | USA |
 |
Annovis Bio
ANVS
|
21.1 M | $ 1.2 | 1.69 % | $ 24.7 M | USA |
 |
Aprea Therapeutics
APRE
|
15.9 M | $ 0.68 | 0.16 % | $ 4.45 M | USA |
 |
Aptevo Therapeutics
APVO
|
27.2 M | $ 1.8 | 2.27 % | $ 568 K | USA |
 |
Aquestive Therapeutics
AQST
|
160 M | $ 4.57 | 0.44 % | $ 489 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
271 M | $ 14.66 | 12.51 % | $ 401 M | Israel |
 |
Ardelyx
ARDX
|
502 M | $ 3.39 | 1.5 % | $ 817 M | USA |
 |
argenx SE
ARGX
|
8.68 B | $ 912.87 | 1.28 % | $ 56 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
76.9 M | $ 3.66 | 3.98 % | $ 133 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
433 M | $ 25.15 | 0.04 % | $ 3.2 B | USA |